Ken Griffin Increases Stake in Eli Lilly Amid Strong Performance
In the second quarter of this year, billionaire Ken Griffin nearly quadrupled Citadel’s stake in Eli Lilly (LLY), adding around 740,000 shares and making it one of his fund's top positions. This move highlights confidence in a company central to two major medical trends: obesity treatment and Alzheimer’s disease management. Eli Lilly reported $23 billion in revenue for Q2 2026, up 48% year-over-year, driven largely by its incretin drugs Mounjaro ($9.9B) and Zepbound ($4.9B). The company is also advancing late-stage obesity treatments like retatrutide and orforglipron while expanding into Alzheimer’s with FDA-approved drug Kisunla (donanemab), which has shown promise in targeting amyloid plaques. Despite its strong performance, Eli Lilly's stock price has surged from under $700 a year ago to around $1,240 today. Analysts have set average price targets near $1,366 per share with some as high as $1,600. While the valuation appears rich compared to traditional pharma peers, many view Lilly more like a growth company due to its focus on obesity and neurological diseases.
Tickers: $LLY
Topics: Alzheimer's treatment Citadel Eli Lilly Ken Griffin Mounjaro obesity drugs Zepbound